Page 20 - Cll News Today

This interview will appear in the January 2024 issue of Evidence-Based Oncology.™ Each year, our January issue features a recap of proceedings from the American Society of Hematology Meeting and Exposition.

The top stories on chronic lymphocytic leukemia from 2023 included topics like BTK inhibitors, minimal residual disease status and approaches to care for various stages of the disease.

Managing a cancer support group isn't easy.

Nicole Lamanna, MD, discusses the results from the ongoing BGB-11417-101 study investigating combination zanubrutinib plus sonrotoclax in patients with treatment-naïve CLL/SLL.

Constantine S. Tam, MD, MBBS, presents the biomarker subgroup analysis from the phase 3 SEQUOIA study investigating zanubrutinib in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma without del(17p).

Paolo Ghia, MD, PhD, describes the various cohorts of the SEQUOIA study, expands on outcomes from a biomarker subgroup analysis with zanubrutinib vs bendamustine plus rituximab, and more.

Our top conference coverage of 2023 covered a range of topics, including cardiovascular disease, heart failure, breast cancer, and chronic lymphocytic leukemia.

Jennifer R. Brown, MD, PhD, discusses the clinical implications of the ALPINE study and highlights a subgroup analysis of acquired mutations in patients with chronic lymphocytic leukemia, demonstrating which mutations were associated with resistance to covalent BTK inhibitors.

Catherine Coombs, MD discusses the present CLL front-line treatment landscape, addressing considerations like choosing fixed-duration or continuous therapy and variations in first-line approaches based on age and ECOG status.

Catherine C. Coombs, MD, presents data investigating venetoclax-based therapy after Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia.